An adhesive interaction between activated platelets and mononuclear phagocytes may contribute to the role these cells play in regulating inflammation, thrombosis, and atherosclerosis. We have previously shown that this adhesive interaction is mediated by the expression of the glycoprotein thrombospondin (TSP) on the surface of activated platelets. We now show that TSP-dependent platelet-monocyte interactions are mediated by glycoprotein IV (GPIV), an intrinsic membrane protein recently identified as a cell surface TSP receptor. Monoclonal antibodies to GPIV bound to cells of the human monocytoid line U937 as assessed by flow cytometry and inhibited the binding of I251-TSP to the cell surface by 83%. U937 cells preincubated with anti-GPIV were not rosetted by thrombinstimulated platelets (72% inhibition compared with control anti-monocyte antibodies). In addition, when platelets were stimulated in the presence of saturating concentrations of monoclonal antibodies to GPIV, only 18% of U937 cells were rosetted (78% inhibition). Control antibodies including antiGPIb did not inhibit rosette formation. These data suggest that TSP can cross-link platelets and monocytes via an interaction with GPIV on the surface of both cells. This molecular bridge may mediate platelet-macrophage communication in various pathophysiologic settings.
Introduction
Cell-cell interactions may play a critical role in regulating the molecular events that occur during inflammation, thrombosis, and atherosclerosis. In particular, an adhesive interaction of activated platelets with mononuclear phagocytes at sites of vascular injury has been shown to be one of the earliest morphologically recognized events in experimental atherosclerosis (1) . In addition, platelets have been shown to influence macrophage activitation and facilitate tissue factor induction (2) while macrophage thromboxane has been shown to potentiate platelet aggregation (3). Jungi et al. (4) have recently described a model system in which thrombin-stimulated human platelets specifically form rosettes with U937 cells (a monocytoid human cell line [5] ) and human monocytes. They found this adhesive interaction to be dependent upon platelet secretion but not upon fibrinogen or fibronectin. We subsequently demReceivedfor publication 8 March 1988 and in revisedform 2 March 1989. onstrated that the adhesive platelet glycoprotein thrombospondin (TSP)' binds specifically and with high affinity to mononuclear phagocytes and that platelet surface TSP mediates this platelet-monocyte interaction (6) . Inhibition studies with both antibodies to TSP and excess TSP suggested that rosette formation was dependent upon the interaction ofplatelet surface TSP with an unidentified receptor on the monocyte surface (6) .
The role of TSP as an adhesive protein and the precise mechanisms of TSP binding to cell surfaces are not yet fully defined. TSP has been shown to mediate cell-cell interactions in several systems in addition to platelet-monocyte adhesion. On the platelet surface, for example, TSP promotes platelet aggregation (7) (8) (9) , and TSP or TSP-like molecules may be involved in the adherence of falciparum malaria-infected red blood cells to endothelium (10) . In addition, several normal and tumor cell lines have been shown to attach and spread on immobilized TSP (11) (12) (13) .
The molecular basis of TSP-cell interactions is complex. Although TSP contains within its primary structure the adhesion sequence RGDA (14, 15) , we have shown that the tetrapeptide RGDS did not inhibit platelet-monocyte adhesion (6) . Similarly TSP did not bind to the purified platelet integrin receptor glycoprotein (GP)IIb/IIIa (16), but did bind normally to platelets genetically deficient in GPIIb/IIIa (17) . Certain monoclonal antibodies to GPIIb/IIIa, however, inhibited TSP binding to platelets (18) , suggesting that GPIIb/IIIa itself or GPIIb/lIla-associated fibrinogen or fibronectin may play a secondary role in TSP-platelet interactions. Thus TSP-platelet interactions seem to be mediated by receptor-ligand interactions different from those of fibronectin, fibrinogen, and vitronectin.
TSP also binds specifically to heparin (19) and sulfated glycolipids (20) . Exogenous heparin effectively inhibited fibroblast and endothelial cell TSP binding and internalization (21, 22) , suggesting that the heparin-binding domain of TSP may mediate this type of cell-TSP interaction perhaps through cell surface-associated heparin-like molecules. Similarly heparin inhibited the spreading of some tumor cells on immobilized TSP (12) . We have previously shown, however, that heparin did not inhibit platelet-monocyte rosette formation or TSP binding to monocytes.
In this paper we identify the monocyte surface TSP receptor immunologically as glycoprotein IV (GPIV). This intrinsic 88-kD, single chain, heavily glycosylated membrane protein, first described in platelets (23) (24) (25) , is also known as GPIIIb and CD36 and is the antigen recognized by the commercially avail-able murine monoclonal antibody OKM5 (26, 27) . This antibody reacts with platelets, monocytes, some endothelial cells (28) , and a variety oftumor cell lines including melanoma C32 and fibrosarcoma HT1080. Studies from this laboratory (29) recently characterized GPIV as a TSP receptor based on the ability of OKM5 to inhibit platelet surface TSP expression and tumor cell TSP binding, as well as by demonstrating specific complex formation of purified TSP with purified GPIV. Monoclonal antibodies to GPIV, however, did not inhibit attachment and spreading of other melanoma lines on TSP (12) nor did they inhibit endothelial cell TSP uptake and degradation (Mosher, D., personal communication).
Methods
Purified proteins. Purified human calcium-replete TSP was prepared from ionophore A23187-induced platelet releasate as previously described (30) Cells and cell culture. U937 cells were maintained as previously described (6) in culture in RPMI-1640 medium (M.A. Bioproducts, Walkersville, MD) supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 gg/ml streptomycin. Cells were subcultured 1:4 three times per week into 75-cm2 flasks. Human PBMC were isolated from dilute citrated whole blood as previously described (6) . Human platelets were isolated from fresh citrated platelet-rich plasma by gel filtration on a column of Sepharose 2B (Pharmacia Fine Chemicals, Piscataway, NJ) as previously described (6) . Platelets were pooled and stimulated under dilute nonstirring conditions with human thrombin (0.2 U/ml) 22°C. After 15 minD-phenylalanyl-L-prolyl-arginine chloromethyl ketone 10-6 M was added for 3 min and then the platelets were lightly fixed with 1.1% formaldehyde at 22°C for 60 min according to the method ofJungi et al. (4) . The fixed platelets were then washed three times and resuspended in buffer containing 2 mg/ml BSA and were used within 24 h of preparation. In some studies the platelets were stimulated either in the presence of monoclonal antibodies to GPIV or control antibodies.
Immunofluorescenceflow cytometry. Washed U937 cells were resuspended in PBS containing 2% BSA and 2% goat serum at 1.8 X 107/ml and 0.1 ml was incubated with monoclonal antibodies (10 ,gg/ml) for 1 h at 22°C. The cells were then washed three times and resuspended in FITC goat anti-mouse IgG in the same buffer for 1 h at 22°C. After repeat washing the cells were resuspended in filtered PBS and immediately analyzed using a flow cytometer equipped with a MDADS data handling computer and an argon laser (Epics; Coulter Instruments, Inc., Hialeah, FL). A wide sizing gate was set by examination of both right angle and forward angle light scatter signals from nonstained cells to include all nucleated cells. For each sample I04 cells were counted within this gate.
Immunoprecipitation. U937 cells (9 X 107) were washed, suspended in 1 ml of PBS, and surface-labeled with 1 mCi '25I-NaI for 20 min at 20°C using N-chloro-benzenesulfonamide-derivatized polystyrene beads (Iodo-Beads; Pierce Chemical Co., Rockford, IL). The cells were then washed four times in cold PBS and lysed in 1 ml of 20 mM Tris, 100 mM NaCl, 1% NP40, 1 mM PMSF, I mM NEM, 1 mM leupeptin, pH 7.2, for 1 h at 4°C. The cytoskeletal and nuclear debris were removed by centrifugation and the lysates cleared by incubation with either goat anti-mouse IgG-agarose beads (Bio-Rad Laboratories, Richmond, CA) or Staphylococcus aureus protein A-agarose beads (Sigma Chemical Co., St. Louis, MO) for 1 h at 4°C. The lysates were then incubated with either monoclonal anti-GPIV IgG (8A6D1 1, IBIG7, OKM5), rabbit anti-GPIV IgG, or nonimmune IgG for 16 h at 4°C. Antigen-antibody complexes were removed by incubation with either goat anti-mouse-agarose beads or protein A-agarose beads that had previously been cleared with nonlabeled U937 lysates. The beads were then extensively washed in lysis buffer containing 0.1% NP40 before resuspension in SDS-PAGE sample buffer. These were boiled for 2 min before electrophoresis under nonreducing conditions on 7.5% SDS-PAGE gels. The gels were fixed and dried, and autoradiographs were obtained using XAR-5 film (Eastman Kodak Co., Rochester, NY). l2I-TSP binding assays. Binding of TSP to U937 cells was quantified as described previously (6) . U937 cells were washed three times, resuspended at 2 x 106 cells/ml, and then incubated in serum-free medium made up of RPMI 1640 containing 2 mg/ml BSA (RPMI/ BSA) for 1 h before use. The cells were then rewashed and aliquoted into 1.5-ml polypropylene microcentrifuge tubes (1.5-2.0 X 106 cells per aliquot, 0.1 ml per tube). To these was added 50 Al of radioiodinated TSP (175 nM) diluted also in RPMI/BSA containing either OKM5 (10 Mg/ml), control anti-monocyte antibodies or EDTA (5 mM). After incubation at 4°C for 1 h the cell suspensions were layered onto 0.4 ml of silicone oil (67:33 vol/vol of No. 550 and 556 oils; Dow Coming Corp., Midland, MI) and centrifuged at 14,000 gin a tabletop microfuge (Beckman Instruments, Inc., Fullerton, CA). The aqueous phase and oil were removed and then the tubes were inverted and the tips containing the cell pellet were amputated and placed in a gamma counter to assess cell-bound radioactivity.
Platelet-monocyte adhesion assay. Platelet-U937 and plateletmonocyte interactions were quantified as previously described (6) Ig/ml murine monoclonal anti-GPIV (OKM5) or with isotype-matched nonimmune mouse IgG for 1 h at 22°C. After washing, the cells were incubated with FITC goat anti-mouse IgG for another hour, washed, and resuspended in filtered PBS, and surface fluorescence was analyzed by flow cytometry. The tracing shows that < 2% of the cells reacted with control antibody (left tracing) whereas > 95% reacted with OKM5.
used to demonstrate that U937 cells express GPIV on their surfaces. Although U937 cells were reported in the initial characterization ofOKM5 not to express this antigen unless stimulated by phorbol esters (26) , we now show, as seen in Fig. 1 also did not inhibit TSP binding. This is consistent with previous reports that platelet surface GPIV is resistant to trypsin digestion (24) . Figure 5 . Role of U937 GPIV in mediating platelet-U937 cell interactions. U937 cells and platelets were incubated as in Fig. 4 cytes or cells of the human monocytoid line U937 by thrombin-stimulated human platelets is mediated by the interaction of platelet surface TSP with an unidentified receptor on the monocyte surface (6). Fig. 4 , A and B, shows a typical rosetting study and demonstrates that thrombin-stimulated platelets but not resting platelets form rosettes around U937 cells. Fig. 4 (Fig. 4 D) . Quantitative analysis of these studies (Fig.  5 ) revealed that 76±8% of U937 cells were rosetted in the presence ofcontrol antibodies whereas 23±5% were rosetted in the presence of OKM5 (72% inhibition). Similar results were obtained with the other monoclonal anti-GPIV antibodies and when peripheral blood monocytes were substituted for U937 cells (Fig. 6 ). In the presence of control anti-monocyte antibodies 73±1 1% of the monocytes were rosetted by thrombin-stimulated platelets, whereas 20±9% were rosetted in the presence of OKM5. These data suggest that the platelet "receptor" on monocytes and U937 cells is GPIV. The ligand for this "receptor" as shown previously is platelet surface-associated TSP. Consistent with this conclusion are data from multiple investigators showing that thrombin-stimulated platelets express surface TSP while resting platelets express little or no TSP ( 18) , and our observations that antibod- under nonstirring conditions in the presence of (A) monoclonal anti-GPIV (OKM5 10 Ag/ml) or (B) monoclonal anti-GPIb (API 20 ug/ml), fixed in formaldehyde, and incubated with U937 cells as in Fig. 4 . Fresh wet mounts were examined by phase-contrast microscopy (X1,000).
ies to TSP as well as excess fluid-phase TSP inhibited rosette formation (6) . We have previously shown that platelet surface TSP expression is inhibited when the platelets were stimulated in the presence of saturating concentrations of OKM5 (29) . Fig. 7 A shows that these platelets do not rosette U937 cells whereas platelets stimulated in the presence ofAP1 (monoclonal anti-GPIb) rosette normally (Fig. 7 B) . Quantitation of these'studies ( Fig. 8) Figure 8 . Role of platelet GPIV in platelet-U937 rosette formation. U937 cells and platelets were incubated as in Fig. 7 (27) . In the studies reported here we now demonstrate that cells of the human monocytoid cell line U937 express GPIV on their surface ( Figs. 1 and 2 ) and that antibodies to GPIV inhibit both direct binding of TSP to the cells (Fig. 3) and TSP-dependent platelet-monocyte adhesion (Fig. 4-6 ). In addition, we have shown previously that platelets activated in the presence of antibodies to GPIV do not express surface TSP (29) and in the present study that these platelets do not form rosettes with U937 cells (Figs. 7 and 8) . The (34) , and histidine-rich glycoprotein (35) , its binding to GPIV on the monocyte/macrophage cell surface may also serve to localize these macromolecules to the area of injury, further contributing to the regulation of thrombosis and pathophysiology of atherosclerosis.
